BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.62B

Market cap10.62B

Price-Earnings ratio

148.83

Price-Earnings ratio148.83

Dividend yield

—

Dividend yield—

Average volume

2.33M

Average volume2.33M

High today

—

High today—

Low today

—

Low today—

Open price

$54.95

Open price$54.95

Volume

0.00

Volume0.00

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

BioMarin(BMRN) stock is priced at $54.80, giving the company a market capitalization of 10.62B. It carries a P/E multiple of 148.83.

On 2026-10-09, BioMarin(BMRN) stock opened at $54.95, reached a high of —, and a low of —.

BioMarin(BMRN) shares are trading with a volume of 0, against a daily average of 2.33M.

In the last year, BioMarin(BMRN) shares hit a 52-week high of $70.98 and a 52-week low of $49.26.

BMRN News

24/7 Wall St. 13h

BMRN Stock Price Prediction 2026-2027 | BioMarin Forecast - 24/7 Wall St.

...

Simply Wall St 21h

Is BioMarin Pharmaceutical Below Fair Value After New Clinical Data And Its AI Deal?

Fresh clinical data and an AI drug discovery deal have pushed BioMarin Pharmaceutical (BMRN) back into focus, as investors weigh what the latest Pompe and Duche...

Simply Wall St 3d

What Does Ascendis Pharma Gain From Its CNP Patent Settlement?

Ascendis Pharma (NasdaqGS:ASND) and BioMarin Pharmaceutical signed a worldwide settlement and license agreement covering C-type natriuretic peptide patents and...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

23.3%

Sell

More BMRN News

TipRanks 4d

BioMarin names Cara Bauer as Chief People Officer

BioMarin (BMRN) Pharmaceutical announced that Cara Bauer, Ph.D., has been named Executive Vice President, Chief People Officer. Bauer will assume responsibility...

TipRanks 7d

BioMarin announces five-year Phase 3 data for POMBILITI plus OPFOLDA

BioMarin (BMRN) Pharmaceutical announced new data evaluating the efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease were presented at the 31...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.